Immune Checkpoint PD-1/PD-L1: Is There Life Beyond Antibodies?

被引：113

作者：

Konstantinidou, Markella ^{[1
]}

Zarganes-Tzitzikas, Tryfon ^{[1
]}

Magiera-Mularz, Katarzyna ^{[2
]}

Holak, Tad A. ^{[2
,3
]}

Domling, Alexander ^{[1
]}

机构：

[1] Univ Groningen, Dept Drug Design, A Deusinglaan 1, NL-9713 AV Groningen, Netherlands

[2] Jagiellonian Univ, Fac Chem, Ingardena 3, PL-30060 Krakow, Poland

[3] Max Planck Inst Biochem, Klopferspitz 18a, D-82152 Martinsried, Germany

来源：

ANGEWANDTE CHEMIE-INTERNATIONAL EDITION | 2018年 / 57卷 / 18期

基金：

新加坡国家研究基金会;

关键词：

antitumor agents; protein-protein interactions; PD-1; PD-L1; protein structures; PROGRAMMED DEATH-1; STRUCTURAL BASIS; CANCER-IMMUNOTHERAPY; CRYSTAL-STRUCTURE; HUMAN PD-1; CELL; INHIBITORS; BLOCKADE; LIGANDS; COMPLEX;

D O I：

10.1002/anie.201710407

中图分类号：

O6 [化学];

学科分类号：

0703 ;

摘要：

The PD-1/PD-L1 interaction has emerged as a significant target in cancer immunotherapy. Current medications include monoclonal antibodies, which have shown impressive clinical results in the treatment of several types of tumors. The cocrystal structure of human PD-1 and PD-L1 is expected to be a valuable starting point for the design of novel inhibitors, along with the recent crystal structures with monoclonal antibodies, small molecules, and macrocycles.

引用

页码：4840 / 4848

页数：9

共 50 条

[21] Predictive biomarkers for PD-1 and PD-L1 immune checkpoint blockade therapy
Song, Yue
Li, Zhaoming
Xue, Weili
Zhang, Mingzhi
IMMUNOTHERAPY, 2019, 11 (06) : 515 - 529
[22] PD-1/PD-L1 checkpoint in hematological malignancies
Annibali, O.
Crescenzi, A.
Tomarchio, V.
Pagano, A.
Bianchi, A.
Grifoni, A.
Avvisati, G.
LEUKEMIA RESEARCH, 2018, 67 : 45 - 55
[23] Targeting Immune Checkpoint Inhibitors for Non-Small-Cell Lung Cancer: Beyond PD-1/PD-L1 Monoclonal Antibodies
Roussot, Nicolas
Kaderbhai, Coureche
Ghiringhelli, Francois
CANCERS, 2025, 17 (05)
[24] Dedifferentiated Endometrial Carcinoma Could be A Target for Immune Checkpoint Inhibitors (Anti PD-1/PD-L1 Antibodies)
Ono, Ruriko
Nakayama, Kentaro
Nakamura, Kohei
Yamashita, Hitomi
Ishibashi, Tomoka
Ishikawa, Masako
Minamoto, Toshiko
Razia, Sultana
Ishikawa, Noriyoshi
Otsuki, Yoshiro
Nakayama, Satoru
Onuma, Hideyuki
Kurioka, Hiroko
Kyo, Satoru
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2019, 20 (15)
[25] New Era Beyond PD-1/PD-L1
Paz-Ares, L.
JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) : S127 - S127
[26] Combination regimens with PD-1/PD-L1 immune checkpoint inhibitors for gastrointestinal malignancies
Wang, Dongxu
Lin, Jianzhen
Yang, Xu
Long, Junyu
Bai, Yi
Yang, Xiaobo
Mao, Yilei
Sang, Xinting
Seery, Samuel
Zhao, Haitao
JOURNAL OF HEMATOLOGY & ONCOLOGY, 2019, 12 (1)
[27] Combination regimens with PD-1/PD-L1 immune checkpoint inhibitors for gastrointestinal malignancies
Dongxu Wang
Jianzhen Lin
Xu Yang
Junyu Long
Yi Bai
Xiaobo Yang
Yilei Mao
Xinting Sang
Samuel Seery
Haitao Zhao
Journal of Hematology & Oncology, 12
[28] PD-1/PD-L1 checkpoint blockade in immune-antitumortherapy:advances and perspectives
Yu LI
Ji JIANG
Bei HU
中国药理学与毒理学杂志, 2017, 31 (10) : 963 - 963
[29] BTN1A1: a novel immune checkpoint for cancer immunotherapy beyond the PD-1/PD-L1 axis.
Chung, Ezra M.
Bong, Yong-Sik
Kim, Young-Seung
Park, Andrew
You, Young-Ok
Sharma, Amrish
Lin, Steven H.
Lee, Young-Joon
Jung, Hyunjin
Yoo, Stephen S.
CANCER RESEARCH, 2021, 81 (13)
[30] PD-1/PD-L1 immune-checkpoint inhibitors in glioblastoma: A concise review
Caccese, Mario
Indraccolo, Stefano
Zagonel, Vittorina
Lombardi, Giuseppe
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2019, 135 : 128 - 134

← 1 2 3 4 5 →